Sanofi India Peer Comparison

NSE: SANOFI | BSE: 500674

₹3,301.40

₹20.50 (0.62%)

As on 13-Nov-2026IST

Market cap

₹7,606 Cr

Revenue (TTM)

₹1,822 Cr

P/E Ratio

20.9

P/B Ratio

8.1

Div. Yield

3.7 %

Edit

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Market cap (₹ Cr)	7,606	19,423	18,167	18,140	17,604
Revenue (₹ Cr)	1,822	1,842	3,330	2,383	2,654
Net Profit (₹ Cr)	364.50	308.62	720.77	700.18	859.38
Net Margin (%)	19.81	16.63	21.60	27.87	30.42
RoE (%)	46.28	11.81	18.93	18.40	18.58
Price to Earnings	20.87	58.43	25.68	26.33	20.48
Price-To-Book	8.07	7.04	4.38	4.65	4.01

Income Statement (₹ Cr)

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Operating Revenue	1,837.40	1,286.43	2,893.64	1,937.47	2,281.35
Total Income	1,857.10	1,322.88	2,912.00	2,033.90	2,453.60
Total Expenditure	1,346.10	980.18	1,876.44	1,290.54	1,541.03
EBITDA	491.30	306.25	1,017.20	646.93	740.32
Depreciation	37.30	112.99	315.46	65.96	60.79
EBIT	454.00	193.26	701.74	580.97	679.53
Interest	1.70	75.53	231.29	0.61	8.50
Other Income	19.70	36.45	18.36	96.43	172.25
Exceptional Items	-27.30	-30.58	--	--	172.81
Profit before Tax	444.70	122.33	488.87	676.78	1,016.09
Provision for Tax	118.00	44.04	114.20	135.69	248.49
Profit after Tax	326.70	78.29	374.67	541.09	767.60

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Shareholder's Funds	749.20	2,362.70	2,854.36	2,850.49	4,217.41
Minority Interest	--	1.04	417.40	35.90	--
Non-Current Liabilities	1,159.50	259.78	2,100.97	13.24	54.89
Current Liabilities	2,514.20	674.19	1,492.79	305.99	569.51
Total Liabilities	4,427.30	3,310.68	6,865.52	3,207.85	4,911.11

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Non-Current Assets	1,599.50	2,313.20	5,531.13	1,071.67	1,328.96
Current Assets	2,823.40	984.51	1,334.39	2,133.95	3,512.85
Total Assets	4,427.30	3,310.68	6,865.52	3,207.85	4,911.11
Total Debt*	0.00	586.37	2,421.66	0.55	2.50
Net Current Assets	309.20	310.32	-158.40	1,827.96	2,943.34
Contingent Liabilities	318.60	76.22	51.96	0.64	363.79

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Cash From Operating Activities	438.30	132.27	1,065.01	432.37	659.75
Cash Flow from Investing Activities	-11.30	-199.13	-79.97	-334.73	-71.34
Cash from Financing Activities	-447.90	62.65	-881.32	-38.32	-205.34
Net Cash Inflow / Outflow	-20.90	-4.21	103.72	59.32	383.07

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
ROCE (%)	55.46	6.95	13.59	26.22	26.21
ROE (%)	44.50	3.75	13.81	21.72	19.65
ROA (%)	7.18	2.45	5.48	18.37	17.03
EBIT Margin (%)	27.81	26.64	35.79	38.37	40.00
Net Margin (%)	17.59	5.92	12.87	26.60	31.28
Cash Profit Margin (%)	17.51	14.87	23.21	31.33	34.70

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Revenue Growth (%)	-8.73	11.71	44.02	14.37	4.02
EBIT Growth (%)	0.73	35.64	48.22	20.21	11.86
Net Profit Growth (%)	4.14	145.00	-5.65	17.27	39.23
EPS Growth (%)	4.14	118.00	-10.39	17.25	39.23
Book Value Growth (%)	-14.39	30.63	10.19	23.77	17.30

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Price / Earnings	28.81	41.41	54.83	28.38	23.86
Price / Book Value	13.89	2.74	6.78	5.52	4.34
Dividend Yield (%)	3.01	0.15	0.52	0.30	4.12
EV/EBITDA	17.88	20.55	20.75	19.78	17.01
Market Cap (₹ Cr)	9,410.98	6,484.12	19,292.77	15,219.80	18,318.10

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Debt to Equity	0.00	0.25	0.85	0.00	0.00
Short term debt to equity ratio	--	0.13	0.14	0.00	0.00
Current Ratio	1.12	1.46	0.89	6.97	6.17
Quick Ratio	1.00	0.94	0.67	5.88	5.33
Interest Coverage	262.59	2.62	3.11	1,110.48	120.54

	Sanofi India	Shilpa Medicare	Eris Lifesciences	Caplin Point Lab	Pfizer
Debtors to sales (%)	9.62	34.26	15.85	32.65	8.46
Asset Turnover	0.46	0.40	0.43	0.66	0.53
Receivable days	35.69	118.15	54.06	110.70	29.10
Inventory Days	71.21	98.29	32.16	65.86	69.53
Payable days	122.11	128.16	140.91	105.88	76.77
Cash Conversion Cycle	-15.20	88.28	-54.69	70.68	21.86

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.